Stay Updated with the Latest Royalty Pharma plc RPRX News in Real Time
Find RPRX news now at Meyka AI. Stay informed with the latest Royalty Pharma plc stocks updates, including price news, market analysis, and expert insights.
Swiss GDP Growth Forecast Jumps to 1.7% for 2026 on Pharma Surge
Switzerland raises 2026 GDP forecast to 1.7% from 0.9% after Q2 growth hits 1.5%, strongest since 2021. Pharma drives half the gains, but inflation expected to rise.
B.C. Election Set for October 24 After Eby Calls Snap Vote
British Columbia Premier David Eby announced a snap provincial election for October 24, 2026, two years early. The vote follows turmoil in the opposition BC Conservatives and Eby’s concerns over U.S. trade threats.
Sensex Falls 121 Points as Brent Crude Hits $108 on September 11
Sensex fell 121 points to 74,781.76 and Nifty dropped 80 points to 23,398.10 on September 11 as Brent crude jumped to $108 amid West Asia conflict and foreign fund outflows.
Prince Harry Accuses UK of Withholding 2023 Al-Qaeda Threat Upon Return
Prince Harry claims UK security officials withheld a 2023 al-Qaeda threat. He returned to Britain last week and is demanding taxpayer-funded police protection for his family.
Sensex Rises 141 Points, Nifty Near 24,100 as IT Stocks Lead Friday’s Intraday Rally
The Sensex rose 141.12 points, or 0.18%, to 77,074.71 as of midday trading on Friday, August 28, 2026. The Nifty 50 added 11.60 points to trade at 24,102.45 during the same intraday window. IT stocks led the session as traders awaited Fed Chair Jerome Powell’s Jackson Hole address. These figures reflect an intraday snapshot around…
AstraZeneca (AZN) and Amgen’s Tezspire Succeeds in Late-Stage Oesophagus Disease Trial
AstraZeneca said Thursday its drug Tezspire met all primary and secondary goals in a late-stage trial. The Phase III CROSSING trial tested Tezspire against placebo in eosinophilic oesophagitis (EoE). AstraZeneca developed the drug jointly with Amgen for this chronic inflammatory oesophagus condition. What the CROSSING Trial Showed The Phase III CROSSING trial evaluated two once-every-four-week…
IPO Subscription Today: Hy Tech Engineers Booked 114x, Skyways 14.4x and Symbiotec 13.86x
IPO subscription today has put Hy Tech Engineers in focus, with the issue reportedly booked 114 times on August 27, 2026. Skyways Air and Symbiotec Pharmalab also saw strong investor demand, with subscriptions of 14.4 times and 13.86 times, respectively. The wide gap between the three issues shows where investors are placing the strongest bets….
Japan’s Whistleblowers Face Retaliation: New Law Tightens Protections in December
Japan’s amended Whistleblower Protection Act, effective December 2026, shifts burden of proof to employers and adds criminal penalties. But gaps remain for harassment and demotion cases.
Strides Pharma Stock Rallies 10% as USFDA Concludes Bengaluru Inspection
Strides Pharma shares surged 11% to ₹1,055.90 on the BSE on August 20, 2026. The rally followed news that the company’s flagship Bengaluru facility received a USFDA Establishment Inspection Report. That report confirms successful closure of a cGMP inspection conducted in May 2026. Heavy trading volumes accompanied the sharp intraday move. What the USFDA EIR…